nodes	percent_of_prediction	percent_of_DWPC	metapath
Thalidomide—hematologic cancer—muscle cancer	0.522	1	CtDrD
Thalidomide—PTGS2—muscle cancer	0.175	1	CbGaD
Thalidomide—CYP1A1—Dacarbazine—muscle cancer	0.0375	0.222	CbGbCtD
Thalidomide—CYP2E1—Dacarbazine—muscle cancer	0.029	0.172	CbGbCtD
Thalidomide—PTGS2—Etoposide—muscle cancer	0.0217	0.129	CbGbCtD
Thalidomide—PTGS1—Etoposide—muscle cancer	0.0184	0.109	CbGbCtD
Thalidomide—CYP1A2—Dacarbazine—muscle cancer	0.0168	0.0993	CbGbCtD
Thalidomide—CYP2E1—Etoposide—muscle cancer	0.0142	0.084	CbGbCtD
Thalidomide—CYP3A5—Vincristine—muscle cancer	0.012	0.0712	CbGbCtD
Thalidomide—CYP3A5—Etoposide—muscle cancer	0.011	0.0653	CbGbCtD
Thalidomide—CYP1A2—Etoposide—muscle cancer	0.0082	0.0486	CbGbCtD
Thalidomide—TNF—vagina—muscle cancer	0.00107	0.0544	CbGeAlD
Thalidomide—CRBN—embryo—muscle cancer	0.000937	0.0474	CbGeAlD
Thalidomide—Lenalidomide—PTGS2—muscle cancer	0.000919	0.518	CrCbGaD
Thalidomide—PTGS2—hindlimb—muscle cancer	0.000896	0.0453	CbGeAlD
Thalidomide—Pomalidomide—PTGS2—muscle cancer	0.000854	0.482	CrCbGaD
Thalidomide—NFKB1—renal system—muscle cancer	0.000846	0.0428	CbGeAlD
Thalidomide—FGFR2—embryo—muscle cancer	0.000839	0.0425	CbGeAlD
Thalidomide—PTGS2—appendage—muscle cancer	0.000768	0.0389	CbGeAlD
Thalidomide—NFKB1—cardiac atrium—muscle cancer	0.000758	0.0383	CbGeAlD
Thalidomide—CRBN—renal system—muscle cancer	0.000709	0.0359	CbGeAlD
Thalidomide—NFKB1—tendon—muscle cancer	0.00066	0.0334	CbGeAlD
Thalidomide—FGFR2—smooth muscle tissue—muscle cancer	0.00066	0.0334	CbGeAlD
Thalidomide—NFKB1—bone marrow—muscle cancer	0.00064	0.0324	CbGeAlD
Thalidomide—FGFR2—renal system—muscle cancer	0.000635	0.0322	CbGeAlD
Thalidomide—CRBN—cardiac atrium—muscle cancer	0.000635	0.0321	CbGeAlD
Thalidomide—NFKB1—vagina—muscle cancer	0.000613	0.031	CbGeAlD
Thalidomide—NFKB1—head—muscle cancer	0.000566	0.0286	CbGeAlD
Thalidomide—CRBN—tendon—muscle cancer	0.000554	0.028	CbGeAlD
Thalidomide—NFKB1—testis—muscle cancer	0.000547	0.0277	CbGeAlD
Thalidomide—CRBN—bone marrow—muscle cancer	0.000536	0.0271	CbGeAlD
Thalidomide—CRBN—vagina—muscle cancer	0.000514	0.026	CbGeAlD
Thalidomide—CRBN—head—muscle cancer	0.000474	0.024	CbGeAlD
Thalidomide—CRBN—testis—muscle cancer	0.000458	0.0232	CbGeAlD
Thalidomide—FGFR2—head—muscle cancer	0.000425	0.0215	CbGeAlD
Thalidomide—FGFR2—testis—muscle cancer	0.000411	0.0208	CbGeAlD
Thalidomide—PTGS2—embryo—muscle cancer	0.000255	0.0129	CbGeAlD
Thalidomide—CYP1A2—renal system—muscle cancer	0.000233	0.0118	CbGeAlD
Thalidomide—CYP1A1—renal system—muscle cancer	0.00023	0.0116	CbGeAlD
Thalidomide—CYP3A5—renal system—muscle cancer	0.000225	0.0114	CbGeAlD
Thalidomide—PTGS1—smooth muscle tissue—muscle cancer	0.00021	0.0106	CbGeAlD
Thalidomide—CYP2E1—renal system—muscle cancer	0.00021	0.0106	CbGeAlD
Thalidomide—CYP2C19—vagina—muscle cancer	0.000207	0.0105	CbGeAlD
Thalidomide—CYP1A1—cardiac atrium—muscle cancer	0.000206	0.0104	CbGeAlD
Thalidomide—PTGS1—renal system—muscle cancer	0.000202	0.0102	CbGeAlD
Thalidomide—PTGS2—smooth muscle tissue—muscle cancer	0.000201	0.0101	CbGeAlD
Thalidomide—PTGS2—renal system—muscle cancer	0.000193	0.00977	CbGeAlD
Thalidomide—PTGS1—cardiac atrium—muscle cancer	0.000181	0.00915	CbGeAlD
Thalidomide—CYP1A1—vagina—muscle cancer	0.000167	0.00843	CbGeAlD
Thalidomide—CYP2E1—tendon—muscle cancer	0.000164	0.00828	CbGeAlD
Thalidomide—CYP3A5—vagina—muscle cancer	0.000163	0.00824	CbGeAlD
Thalidomide—PTGS1—tendon—muscle cancer	0.000158	0.00798	CbGeAlD
Thalidomide—CYP1A1—head—muscle cancer	0.000154	0.00778	CbGeAlD
Thalidomide—PTGS2—tendon—muscle cancer	0.000151	0.00763	CbGeAlD
Thalidomide—PTGS1—vagina—muscle cancer	0.000146	0.0074	CbGeAlD
Thalidomide—PTGS2—bone marrow—muscle cancer	0.000146	0.00739	CbGeAlD
Thalidomide—CYP2E1—head—muscle cancer	0.00014	0.0071	CbGeAlD
Thalidomide—PTGS2—vagina—muscle cancer	0.00014	0.00708	CbGeAlD
Thalidomide—CYP2E1—testis—muscle cancer	0.000136	0.00686	CbGeAlD
Thalidomide—PTGS1—head—muscle cancer	0.000135	0.00684	CbGeAlD
Thalidomide—PTGS1—testis—muscle cancer	0.000131	0.00661	CbGeAlD
Thalidomide—PTGS2—head—muscle cancer	0.000129	0.00654	CbGeAlD
Thalidomide—FGFR2—Downstream signal transduction—FOXO1—muscle cancer	9.14e-05	0.00242	CbGpPWpGaD
Thalidomide—TNF—Aryl Hydrocarbon Receptor—VEGFA—muscle cancer	9.12e-05	0.00241	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by FGFR—FOXO1—muscle cancer	9.1e-05	0.0024	CbGpPWpGaD
Thalidomide—NFKB1—Oncostatin M Signaling Pathway—VEGFA—muscle cancer	9.07e-05	0.0024	CbGpPWpGaD
Thalidomide—FGFR2—Constitutive PI3K/AKT Signaling in Cancer—MDM2—muscle cancer	9.06e-05	0.00239	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by ERBB2—FOXO1—muscle cancer	9.05e-05	0.00239	CbGpPWpGaD
Thalidomide—NFKB1—Selenium Micronutrient Network—PTGS2—muscle cancer	9.04e-05	0.00239	CbGpPWpGaD
Thalidomide—FGFR2—DAP12 signaling—FOXO1—muscle cancer	9.01e-05	0.00238	CbGpPWpGaD
Thalidomide—NFKB1—Fc epsilon receptor (FCERI) signaling—FOXO1—muscle cancer	8.93e-05	0.00236	CbGpPWpGaD
Thalidomide—FGFR2—Downstream signaling events of B Cell Receptor (BCR)—FOXO1—muscle cancer	8.88e-05	0.00235	CbGpPWpGaD
Thalidomide—TNF—Adipogenesis—FOXO1—muscle cancer	8.71e-05	0.0023	CbGpPWpGaD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—BUB1B—muscle cancer	8.67e-05	0.00229	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by FGFR in disease—FOXO1—muscle cancer	8.48e-05	0.00224	CbGpPWpGaD
Thalidomide—FGFR2—DAP12 interactions—FOXO1—muscle cancer	8.48e-05	0.00224	CbGpPWpGaD
Thalidomide—FGFR2—Fc epsilon receptor (FCERI) signaling—FOXO1—muscle cancer	8.48e-05	0.00224	CbGpPWpGaD
Thalidomide—PTGS1—Arachidonic acid metabolism—PTGS2—muscle cancer	8.43e-05	0.00223	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by EGFR—FOXO1—muscle cancer	8.4e-05	0.00222	CbGpPWpGaD
Thalidomide—NFKB1—Senescence-Associated Secretory Phenotype (SASP)—CDKN2A—muscle cancer	8.39e-05	0.00222	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by EGFR in Cancer—FOXO1—muscle cancer	8.33e-05	0.0022	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by PDGF—FOXO1—muscle cancer	8.29e-05	0.00219	CbGpPWpGaD
Thalidomide—NFKB1—B Cell Activation—FOXO1—muscle cancer	8.27e-05	0.00219	CbGpPWpGaD
Thalidomide—NFKB1—Signaling by NGF—FOXO4—muscle cancer	8.24e-05	0.00218	CbGpPWpGaD
Thalidomide—FGFR2—PI-3K cascade—MDM2—muscle cancer	8.16e-05	0.00216	CbGpPWpGaD
Thalidomide—NFKB1—DNA Damage Response (only ATM dependent)—CDKN2A—muscle cancer	8.15e-05	0.00215	CbGpPWpGaD
Thalidomide—TNF—Amyotrophic lateral sclerosis (ALS)—TP53—muscle cancer	8.03e-05	0.00212	CbGpPWpGaD
Thalidomide—FGFR2—PI3K/AKT activation—MDM2—muscle cancer	7.97e-05	0.00211	CbGpPWpGaD
Thalidomide—FGFR2—GAB1 signalosome—MDM2—muscle cancer	7.91e-05	0.00209	CbGpPWpGaD
Thalidomide—NFKB1—DNA Damage Response (only ATM dependent)—MDM2—muscle cancer	7.9e-05	0.00209	CbGpPWpGaD
Thalidomide—FGFR2—B Cell Activation—FOXO1—muscle cancer	7.85e-05	0.00207	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—MYOD1—muscle cancer	7.83e-05	0.00207	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by NGF—FOXO4—muscle cancer	7.82e-05	0.00207	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by SCF-KIT—KIT—muscle cancer	7.75e-05	0.00205	CbGpPWpGaD
Thalidomide—FGFR2—Role of LAT2/NTAL/LAB on calcium mobilization—MDM2—muscle cancer	7.72e-05	0.00204	CbGpPWpGaD
Thalidomide—TNF—Apoptosis—CDKN2A—muscle cancer	7.65e-05	0.00202	CbGpPWpGaD
Thalidomide—FGFR2—NGF signalling via TRKA from the plasma membrane—FOXO1—muscle cancer	7.51e-05	0.00198	CbGpPWpGaD
Thalidomide—TNF—Apoptosis—MDM2—muscle cancer	7.42e-05	0.00196	CbGpPWpGaD
Thalidomide—FGFR2—Downstream signaling of activated FGFR—KIT—muscle cancer	7.41e-05	0.00196	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—WT1—muscle cancer	7.34e-05	0.00194	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by ERBB4—KIT—muscle cancer	7.3e-05	0.00193	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—MED12—muscle cancer	7.16e-05	0.00189	CbGpPWpGaD
Thalidomide—NFKB1—Downstream signaling events of B Cell Receptor (BCR)—KIT—muscle cancer	7.13e-05	0.00188	CbGpPWpGaD
Thalidomide—CYP2E1—Tryptophan metabolism—MDM2—muscle cancer	6.99e-05	0.00185	CbGpPWpGaD
Thalidomide—FGFR2—Downstream signal transduction—KIT—muscle cancer	6.97e-05	0.00184	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by FGFR—KIT—muscle cancer	6.93e-05	0.00183	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by ERBB2—KIT—muscle cancer	6.9e-05	0.00182	CbGpPWpGaD
Thalidomide—TNF—Selenium Micronutrient Network—PTGS2—muscle cancer	6.89e-05	0.00182	CbGpPWpGaD
Thalidomide—FGFR2—DAP12 signaling—KIT—muscle cancer	6.87e-05	0.00181	CbGpPWpGaD
Thalidomide—NFKB1—Oncostatin M Signaling Pathway—TP53—muscle cancer	6.86e-05	0.00181	CbGpPWpGaD
Thalidomide—NFKB1—Fc epsilon receptor (FCERI) signaling—KIT—muscle cancer	6.81e-05	0.0018	CbGpPWpGaD
Thalidomide—NFKB1—Folate Metabolism—TP53—muscle cancer	6.77e-05	0.00179	CbGpPWpGaD
Thalidomide—FGFR2—Downstream signaling events of B Cell Receptor (BCR)—KIT—muscle cancer	6.77e-05	0.00179	CbGpPWpGaD
Thalidomide—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—MED12—muscle cancer	6.72e-05	0.00177	CbGpPWpGaD
Thalidomide—NFKB1—Rac1/Pak1/p38/MMP-2 pathway—TP53—muscle cancer	6.69e-05	0.00177	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—CD34—muscle cancer	6.64e-05	0.00175	CbGpPWpGaD
Thalidomide—CYP1A1—Tryptophan metabolism—MDM2—muscle cancer	6.59e-05	0.00174	CbGpPWpGaD
Thalidomide—FGFR2—Fc epsilon receptor (FCERI) signaling—KIT—muscle cancer	6.46e-05	0.00171	CbGpPWpGaD
Thalidomide—FGFR2—DAP12 interactions—KIT—muscle cancer	6.46e-05	0.00171	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by FGFR in disease—KIT—muscle cancer	6.46e-05	0.00171	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by EGFR—KIT—muscle cancer	6.4e-05	0.00169	CbGpPWpGaD
Thalidomide—CYP1A1—Aryl Hydrocarbon Receptor—PTGS2—muscle cancer	6.35e-05	0.00168	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by EGFR in Cancer—KIT—muscle cancer	6.34e-05	0.00168	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by PDGF—KIT—muscle cancer	6.32e-05	0.00167	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—CD34—muscle cancer	6.3e-05	0.00166	CbGpPWpGaD
Thalidomide—NFKB1—B Cell Activation—KIT—muscle cancer	6.3e-05	0.00166	CbGpPWpGaD
Thalidomide—Asthenia—Dactinomycin—muscle cancer	6.19e-05	0.000823	CcSEcCtD
Thalidomide—Blood creatinine increased—Doxorubicin—muscle cancer	6.18e-05	0.000821	CcSEcCtD
Thalidomide—Neutropenia—Methotrexate—muscle cancer	6.15e-05	0.000818	CcSEcCtD
Thalidomide—Dehydration—Doxorubicin—muscle cancer	6.13e-05	0.000815	CcSEcCtD
Thalidomide—Thrombocytopenia—Etoposide—muscle cancer	6.12e-05	0.000813	CcSEcCtD
Thalidomide—Upper respiratory tract infection—Methotrexate—muscle cancer	6.11e-05	0.000813	CcSEcCtD
Thalidomide—FGFR2—Signaling by SCF-KIT—MDM2—muscle cancer	6.1e-05	0.00161	CbGpPWpGaD
Thalidomide—Tachycardia—Etoposide—muscle cancer	6.1e-05	0.00081	CcSEcCtD
Thalidomide—Body temperature increased—Vincristine—muscle cancer	6.1e-05	0.00081	CcSEcCtD
Thalidomide—Abdominal pain—Vincristine—muscle cancer	6.1e-05	0.00081	CcSEcCtD
Thalidomide—NFKB1—Integrated Breast Cancer Pathway—MDM2—muscle cancer	6.09e-05	0.00161	CbGpPWpGaD
Thalidomide—NFKB1—Signaling by NGF—FOXO1—muscle cancer	6.09e-05	0.00161	CbGpPWpGaD
Thalidomide—Liver function test abnormal—Doxorubicin—muscle cancer	6.09e-05	0.000809	CcSEcCtD
Thalidomide—Skin disorder—Etoposide—muscle cancer	6.07e-05	0.000807	CcSEcCtD
Thalidomide—Erectile dysfunction—Methotrexate—muscle cancer	6.06e-05	0.000806	CcSEcCtD
Thalidomide—Dry skin—Doxorubicin—muscle cancer	6.04e-05	0.000803	CcSEcCtD
Thalidomide—Hyperhidrosis—Etoposide—muscle cancer	6.04e-05	0.000803	CcSEcCtD
Thalidomide—Orthostatic hypotension—Doxorubicin—muscle cancer	6.02e-05	0.0008	CcSEcCtD
Thalidomide—Photosensitivity reaction—Methotrexate—muscle cancer	6.01e-05	0.000798	CcSEcCtD
Thalidomide—Hypokalaemia—Doxorubicin—muscle cancer	6e-05	0.000797	CcSEcCtD
Thalidomide—FGFR2—B Cell Activation—KIT—muscle cancer	5.98e-05	0.00158	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—MYOD1—muscle cancer	5.97e-05	0.00158	CbGpPWpGaD
Thalidomide—Breast disorder—Doxorubicin—muscle cancer	5.96e-05	0.000792	CcSEcCtD
Thalidomide—Anorexia—Etoposide—muscle cancer	5.95e-05	0.000791	CcSEcCtD
Thalidomide—CYP1A1—Arachidonic acid metabolism—PTGS2—muscle cancer	5.94e-05	0.00157	CbGpPWpGaD
Thalidomide—Aspartate aminotransferase increased—Doxorubicin—muscle cancer	5.94e-05	0.000789	CcSEcCtD
Thalidomide—Toxic epidermal necrolysis—Doxorubicin—muscle cancer	5.94e-05	0.000789	CcSEcCtD
Thalidomide—TNF—Allograft Rejection—VEGFA—muscle cancer	5.91e-05	0.00156	CbGpPWpGaD
Thalidomide—Diarrhoea—Dactinomycin—muscle cancer	5.9e-05	0.000785	CcSEcCtD
Thalidomide—Pneumonia—Methotrexate—muscle cancer	5.9e-05	0.000784	CcSEcCtD
Thalidomide—Infestation NOS—Methotrexate—muscle cancer	5.87e-05	0.00078	CcSEcCtD
Thalidomide—Drowsiness—Methotrexate—muscle cancer	5.87e-05	0.00078	CcSEcCtD
Thalidomide—Infestation—Methotrexate—muscle cancer	5.87e-05	0.00078	CcSEcCtD
Thalidomide—Depression—Methotrexate—muscle cancer	5.85e-05	0.000778	CcSEcCtD
Thalidomide—FGFR2—Downstream signaling of activated FGFR—MDM2—muscle cancer	5.84e-05	0.00154	CbGpPWpGaD
Thalidomide—Hypotension—Etoposide—muscle cancer	5.84e-05	0.000776	CcSEcCtD
Thalidomide—PTGS2—C-MYB transcription factor network—KIT—muscle cancer	5.82e-05	0.00154	CbGpPWpGaD
Thalidomide—Stevens-Johnson syndrome—Methotrexate—muscle cancer	5.82e-05	0.000773	CcSEcCtD
Thalidomide—Alanine aminotransferase increased—Doxorubicin—muscle cancer	5.81e-05	0.000773	CcSEcCtD
Thalidomide—Muscular weakness—Doxorubicin—muscle cancer	5.81e-05	0.000773	CcSEcCtD
Thalidomide—FGFR2—Signaling by NGF—FOXO1—muscle cancer	5.77e-05	0.00153	CbGpPWpGaD
Thalidomide—Renal failure—Methotrexate—muscle cancer	5.77e-05	0.000767	CcSEcCtD
Thalidomide—FGFR2—Signaling by ERBB4—MDM2—muscle cancer	5.75e-05	0.00152	CbGpPWpGaD
Thalidomide—Abdominal distension—Doxorubicin—muscle cancer	5.74e-05	0.000762	CcSEcCtD
Thalidomide—FGFR2—NGF signalling via TRKA from the plasma membrane—KIT—muscle cancer	5.72e-05	0.00151	CbGpPWpGaD
Thalidomide—Stomatitis—Methotrexate—muscle cancer	5.72e-05	0.00076	CcSEcCtD
Thalidomide—Conjunctivitis—Methotrexate—muscle cancer	5.7e-05	0.000758	CcSEcCtD
Thalidomide—Influenza—Doxorubicin—muscle cancer	5.7e-05	0.000757	CcSEcCtD
Thalidomide—Dysphagia—Doxorubicin—muscle cancer	5.7e-05	0.000757	CcSEcCtD
Thalidomide—NFKB1—Glucocorticoid receptor regulatory network—TP53—muscle cancer	5.69e-05	0.0015	CbGpPWpGaD
Thalidomide—Hypersensitivity—Vincristine—muscle cancer	5.68e-05	0.000755	CcSEcCtD
Thalidomide—Eosinophilia—Doxorubicin—muscle cancer	5.64e-05	0.00075	CcSEcCtD
Thalidomide—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—muscle cancer	5.64e-05	0.00149	CbGpPWpGaD
Thalidomide—Sweating—Methotrexate—muscle cancer	5.62e-05	0.000748	CcSEcCtD
Thalidomide—NFKB1—Downstream signaling events of B Cell Receptor (BCR)—MDM2—muscle cancer	5.62e-05	0.00148	CbGpPWpGaD
Thalidomide—Paraesthesia—Etoposide—muscle cancer	5.61e-05	0.000746	CcSEcCtD
Thalidomide—Haematuria—Methotrexate—muscle cancer	5.59e-05	0.000744	CcSEcCtD
Thalidomide—Pancreatitis—Doxorubicin—muscle cancer	5.59e-05	0.000743	CcSEcCtD
Thalidomide—NFKB1—Apoptosis—TP53—muscle cancer	5.58e-05	0.00148	CbGpPWpGaD
Thalidomide—Dyspnoea—Etoposide—muscle cancer	5.57e-05	0.00074	CcSEcCtD
Thalidomide—Somnolence—Etoposide—muscle cancer	5.55e-05	0.000738	CcSEcCtD
Thalidomide—Angina pectoris—Doxorubicin—muscle cancer	5.55e-05	0.000738	CcSEcCtD
Thalidomide—Epistaxis—Methotrexate—muscle cancer	5.53e-05	0.000736	CcSEcCtD
Thalidomide—Asthenia—Vincristine—muscle cancer	5.53e-05	0.000735	CcSEcCtD
Thalidomide—FGFR2—Downstream signal transduction—MDM2—muscle cancer	5.49e-05	0.00145	CbGpPWpGaD
Thalidomide—Vomiting—Dactinomycin—muscle cancer	5.49e-05	0.000729	CcSEcCtD
Thalidomide—Bronchitis—Doxorubicin—muscle cancer	5.48e-05	0.000728	CcSEcCtD
Thalidomide—Agranulocytosis—Methotrexate—muscle cancer	5.47e-05	0.000728	CcSEcCtD
Thalidomide—FGFR2—Signaling by FGFR—MDM2—muscle cancer	5.46e-05	0.00144	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—MED12—muscle cancer	5.46e-05	0.00144	CbGpPWpGaD
Thalidomide—TNF—Spinal Cord Injury—PTGS2—muscle cancer	5.45e-05	0.00144	CbGpPWpGaD
Thalidomide—Rash—Dactinomycin—muscle cancer	5.44e-05	0.000723	CcSEcCtD
Thalidomide—FGFR2—Signaling by ERBB2—MDM2—muscle cancer	5.43e-05	0.00144	CbGpPWpGaD
Thalidomide—Decreased appetite—Etoposide—muscle cancer	5.43e-05	0.000722	CcSEcCtD
Thalidomide—Pancytopenia—Doxorubicin—muscle cancer	5.41e-05	0.000719	CcSEcCtD
Thalidomide—FGFR2—DAP12 signaling—MDM2—muscle cancer	5.41e-05	0.00143	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways in Glioblastoma—TP53—muscle cancer	5.4e-05	0.00143	CbGpPWpGaD
Thalidomide—Gastrointestinal disorder—Etoposide—muscle cancer	5.39e-05	0.000717	CcSEcCtD
Thalidomide—Fatigue—Etoposide—muscle cancer	5.39e-05	0.000716	CcSEcCtD
Thalidomide—PTGS1—Selenium Micronutrient Network—PTGS2—muscle cancer	5.37e-05	0.00142	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—BUB1B—muscle cancer	5.36e-05	0.00142	CbGpPWpGaD
Thalidomide—NFKB1—Fc epsilon receptor (FCERI) signaling—MDM2—muscle cancer	5.36e-05	0.00142	CbGpPWpGaD
Thalidomide—Constipation—Etoposide—muscle cancer	5.34e-05	0.00071	CcSEcCtD
Thalidomide—Pain—Etoposide—muscle cancer	5.34e-05	0.00071	CcSEcCtD
Thalidomide—FGFR2—Downstream signaling events of B Cell Receptor (BCR)—MDM2—muscle cancer	5.33e-05	0.00141	CbGpPWpGaD
Thalidomide—Neutropenia—Doxorubicin—muscle cancer	5.33e-05	0.000708	CcSEcCtD
Thalidomide—NFKB1—Cellular Senescence—CDKN2A—muscle cancer	5.31e-05	0.0014	CbGpPWpGaD
Thalidomide—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—muscle cancer	5.3e-05	0.0014	CbGpPWpGaD
Thalidomide—Upper respiratory tract infection—Doxorubicin—muscle cancer	5.29e-05	0.000704	CcSEcCtD
Thalidomide—Diarrhoea—Vincristine—muscle cancer	5.28e-05	0.000701	CcSEcCtD
Thalidomide—Hepatitis—Methotrexate—muscle cancer	5.27e-05	0.0007	CcSEcCtD
Thalidomide—Pollakiuria—Doxorubicin—muscle cancer	5.26e-05	0.0007	CcSEcCtD
Thalidomide—NFKB1—Apoptosis Modulation and Signaling—TP53—muscle cancer	5.24e-05	0.00138	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—KIDINS220—muscle cancer	5.23e-05	0.00138	CbGpPWpGaD
Thalidomide—Pharyngitis—Methotrexate—muscle cancer	5.23e-05	0.000695	CcSEcCtD
Thalidomide—Urinary tract disorder—Methotrexate—muscle cancer	5.2e-05	0.000691	CcSEcCtD
Thalidomide—Photosensitivity reaction—Doxorubicin—muscle cancer	5.2e-05	0.000691	CcSEcCtD
Thalidomide—Weight increased—Doxorubicin—muscle cancer	5.18e-05	0.000689	CcSEcCtD
Thalidomide—Urethral disorder—Methotrexate—muscle cancer	5.16e-05	0.000686	CcSEcCtD
Thalidomide—TNF—Folate Metabolism—TP53—muscle cancer	5.16e-05	0.00136	CbGpPWpGaD
Thalidomide—Weight decreased—Doxorubicin—muscle cancer	5.15e-05	0.000685	CcSEcCtD
Thalidomide—NFKB1—Cellular Senescence—MDM2—muscle cancer	5.15e-05	0.00136	CbGpPWpGaD
Thalidomide—Feeling abnormal—Etoposide—muscle cancer	5.15e-05	0.000684	CcSEcCtD
Thalidomide—Hyperglycaemia—Doxorubicin—muscle cancer	5.14e-05	0.000683	CcSEcCtD
Thalidomide—Nausea—Dactinomycin—muscle cancer	5.13e-05	0.000681	CcSEcCtD
Thalidomide—Pneumonia—Doxorubicin—muscle cancer	5.11e-05	0.000679	CcSEcCtD
Thalidomide—Gastrointestinal pain—Etoposide—muscle cancer	5.11e-05	0.000679	CcSEcCtD
Thalidomide—Dizziness—Vincristine—muscle cancer	5.1e-05	0.000678	CcSEcCtD
Thalidomide—FGFR2—Fc epsilon receptor (FCERI) signaling—MDM2—muscle cancer	5.09e-05	0.00134	CbGpPWpGaD
Thalidomide—FGFR2—DAP12 interactions—MDM2—muscle cancer	5.09e-05	0.00134	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by FGFR in disease—MDM2—muscle cancer	5.09e-05	0.00134	CbGpPWpGaD
Thalidomide—Infestation NOS—Doxorubicin—muscle cancer	5.08e-05	0.000675	CcSEcCtD
Thalidomide—Infestation—Doxorubicin—muscle cancer	5.08e-05	0.000675	CcSEcCtD
Thalidomide—Drowsiness—Doxorubicin—muscle cancer	5.08e-05	0.000675	CcSEcCtD
Thalidomide—Visual impairment—Methotrexate—muscle cancer	5.07e-05	0.000675	CcSEcCtD
Thalidomide—NFKB1—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	5.04e-05	0.00133	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by EGFR—MDM2—muscle cancer	5.04e-05	0.00133	CbGpPWpGaD
Thalidomide—Stevens-Johnson syndrome—Doxorubicin—muscle cancer	5.04e-05	0.000669	CcSEcCtD
Thalidomide—CYP1A1—Aryl Hydrocarbon Receptor—VEGFA—muscle cancer	5e-05	0.00132	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by EGFR in Cancer—MDM2—muscle cancer	5e-05	0.00132	CbGpPWpGaD
Thalidomide—Renal failure—Doxorubicin—muscle cancer	4.99e-05	0.000664	CcSEcCtD
Thalidomide—Erythema multiforme—Methotrexate—muscle cancer	4.98e-05	0.000662	CcSEcCtD
Thalidomide—Neuropathy peripheral—Doxorubicin—muscle cancer	4.98e-05	0.000662	CcSEcCtD
Thalidomide—FGFR2—Signaling by PDGF—MDM2—muscle cancer	4.97e-05	0.00131	CbGpPWpGaD
Thalidomide—Urticaria—Etoposide—muscle cancer	4.96e-05	0.00066	CcSEcCtD
Thalidomide—NFKB1—B Cell Activation—MDM2—muscle cancer	4.96e-05	0.00131	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—KIDINS220—muscle cancer	4.96e-05	0.00131	CbGpPWpGaD
Thalidomide—Stomatitis—Doxorubicin—muscle cancer	4.95e-05	0.000658	CcSEcCtD
Thalidomide—Abdominal pain—Etoposide—muscle cancer	4.94e-05	0.000656	CcSEcCtD
Thalidomide—Body temperature increased—Etoposide—muscle cancer	4.94e-05	0.000656	CcSEcCtD
Thalidomide—Conjunctivitis—Doxorubicin—muscle cancer	4.94e-05	0.000656	CcSEcCtD
Thalidomide—Eye disorder—Methotrexate—muscle cancer	4.92e-05	0.000654	CcSEcCtD
Thalidomide—Tinnitus—Methotrexate—muscle cancer	4.91e-05	0.000653	CcSEcCtD
Thalidomide—Vomiting—Vincristine—muscle cancer	4.9e-05	0.000652	CcSEcCtD
Thalidomide—Cardiac disorder—Methotrexate—muscle cancer	4.89e-05	0.00065	CcSEcCtD
Thalidomide—Sweating—Doxorubicin—muscle cancer	4.87e-05	0.000647	CcSEcCtD
Thalidomide—NFKB1—Integrated Pancreatic Cancer Pathway—PTGS2—muscle cancer	4.86e-05	0.00129	CbGpPWpGaD
Thalidomide—CYP2C19—Arachidonic acid metabolism—PTGS2—muscle cancer	4.86e-05	0.00129	CbGpPWpGaD
Thalidomide—Rash—Vincristine—muscle cancer	4.86e-05	0.000646	CcSEcCtD
Thalidomide—Dermatitis—Vincristine—muscle cancer	4.86e-05	0.000646	CcSEcCtD
Thalidomide—Haematuria—Doxorubicin—muscle cancer	4.84e-05	0.000644	CcSEcCtD
Thalidomide—Headache—Vincristine—muscle cancer	4.83e-05	0.000642	CcSEcCtD
Thalidomide—Epistaxis—Doxorubicin—muscle cancer	4.79e-05	0.000637	CcSEcCtD
Thalidomide—Angiopathy—Methotrexate—muscle cancer	4.78e-05	0.000635	CcSEcCtD
Thalidomide—Sinusitis—Doxorubicin—muscle cancer	4.77e-05	0.000634	CcSEcCtD
Thalidomide—Immune system disorder—Methotrexate—muscle cancer	4.76e-05	0.000632	CcSEcCtD
Thalidomide—Mediastinal disorder—Methotrexate—muscle cancer	4.75e-05	0.000631	CcSEcCtD
Thalidomide—Agranulocytosis—Doxorubicin—muscle cancer	4.74e-05	0.00063	CcSEcCtD
Thalidomide—PTGS2—C-MYB transcription factor network—CDKN2A—muscle cancer	4.73e-05	0.00125	CbGpPWpGaD
Thalidomide—Chills—Methotrexate—muscle cancer	4.73e-05	0.000628	CcSEcCtD
Thalidomide—FGFR2—B Cell Activation—MDM2—muscle cancer	4.71e-05	0.00124	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—FOXO4—muscle cancer	4.7e-05	0.00124	CbGpPWpGaD
Thalidomide—Alopecia—Methotrexate—muscle cancer	4.65e-05	0.000619	CcSEcCtD
Thalidomide—Bradycardia—Doxorubicin—muscle cancer	4.64e-05	0.000617	CcSEcCtD
Thalidomide—NFKB1—Signaling by NGF—KIT—muscle cancer	4.64e-05	0.00123	CbGpPWpGaD
Thalidomide—NFKB1—Integrated Breast Cancer Pathway—VEGFA—muscle cancer	4.62e-05	0.00122	CbGpPWpGaD
Thalidomide—Mental disorder—Methotrexate—muscle cancer	4.61e-05	0.000613	CcSEcCtD
Thalidomide—Hypersensitivity—Etoposide—muscle cancer	4.6e-05	0.000612	CcSEcCtD
Thalidomide—Malnutrition—Methotrexate—muscle cancer	4.58e-05	0.000609	CcSEcCtD
Thalidomide—Nausea—Vincristine—muscle cancer	4.58e-05	0.000609	CcSEcCtD
Thalidomide—Rhinitis—Doxorubicin—muscle cancer	4.57e-05	0.000608	CcSEcCtD
Thalidomide—Hepatitis—Doxorubicin—muscle cancer	4.56e-05	0.000606	CcSEcCtD
Thalidomide—Hypoaesthesia—Doxorubicin—muscle cancer	4.54e-05	0.000603	CcSEcCtD
Thalidomide—NFKB1—DNA Damage Response (only ATM dependent)—TP53—muscle cancer	4.53e-05	0.0012	CbGpPWpGaD
Thalidomide—Pharyngitis—Doxorubicin—muscle cancer	4.53e-05	0.000602	CcSEcCtD
Thalidomide—NFKB1—Adaptive Immune System—FOXO4—muscle cancer	4.51e-05	0.00119	CbGpPWpGaD
Thalidomide—FGFR2—NGF signalling via TRKA from the plasma membrane—MDM2—muscle cancer	4.51e-05	0.00119	CbGpPWpGaD
Thalidomide—NFKB1—SIDS Susceptibility Pathways—VEGFA—muscle cancer	4.5e-05	0.00119	CbGpPWpGaD
Thalidomide—Urinary tract disorder—Doxorubicin—muscle cancer	4.5e-05	0.000599	CcSEcCtD
Thalidomide—Oedema peripheral—Doxorubicin—muscle cancer	4.49e-05	0.000597	CcSEcCtD
Thalidomide—Dysgeusia—Methotrexate—muscle cancer	4.49e-05	0.000597	CcSEcCtD
Thalidomide—Asthenia—Etoposide—muscle cancer	4.48e-05	0.000596	CcSEcCtD
Thalidomide—Urethral disorder—Doxorubicin—muscle cancer	4.47e-05	0.000594	CcSEcCtD
Thalidomide—TNF—Alzheimers Disease—TP53—muscle cancer	4.47e-05	0.00118	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—FOXO4—muscle cancer	4.46e-05	0.00118	CbGpPWpGaD
Thalidomide—Back pain—Methotrexate—muscle cancer	4.43e-05	0.000589	CcSEcCtD
Thalidomide—CYP2C9—Arachidonic acid metabolism—PTGS2—muscle cancer	4.43e-05	0.00117	CbGpPWpGaD
Thalidomide—Pruritus—Etoposide—muscle cancer	4.42e-05	0.000587	CcSEcCtD
Thalidomide—FGFR2—Signaling by NGF—KIT—muscle cancer	4.4e-05	0.00116	CbGpPWpGaD
Thalidomide—Visual impairment—Doxorubicin—muscle cancer	4.39e-05	0.000584	CcSEcCtD
Thalidomide—Vision blurred—Methotrexate—muscle cancer	4.32e-05	0.000574	CcSEcCtD
Thalidomide—Erythema multiforme—Doxorubicin—muscle cancer	4.31e-05	0.000573	CcSEcCtD
Thalidomide—FGFR2—Adaptive Immune System—FOXO4—muscle cancer	4.28e-05	0.00113	CbGpPWpGaD
Thalidomide—Diarrhoea—Etoposide—muscle cancer	4.27e-05	0.000568	CcSEcCtD
Thalidomide—Eye disorder—Doxorubicin—muscle cancer	4.26e-05	0.000566	CcSEcCtD
Thalidomide—TNF—Apoptosis—TP53—muscle cancer	4.25e-05	0.00112	CbGpPWpGaD
Thalidomide—Ill-defined disorder—Methotrexate—muscle cancer	4.25e-05	0.000565	CcSEcCtD
Thalidomide—Tinnitus—Doxorubicin—muscle cancer	4.25e-05	0.000565	CcSEcCtD
Thalidomide—Anaemia—Methotrexate—muscle cancer	4.24e-05	0.000563	CcSEcCtD
Thalidomide—Cardiac disorder—Doxorubicin—muscle cancer	4.23e-05	0.000563	CcSEcCtD
Thalidomide—CYP1A2—Tryptophan metabolism—MDM2—muscle cancer	4.2e-05	0.00111	CbGpPWpGaD
Thalidomide—Angiopathy—Doxorubicin—muscle cancer	4.14e-05	0.00055	CcSEcCtD
Thalidomide—Malaise—Methotrexate—muscle cancer	4.13e-05	0.00055	CcSEcCtD
Thalidomide—Dizziness—Etoposide—muscle cancer	4.13e-05	0.000549	CcSEcCtD
Thalidomide—Immune system disorder—Doxorubicin—muscle cancer	4.12e-05	0.000548	CcSEcCtD
Thalidomide—Vertigo—Methotrexate—muscle cancer	4.12e-05	0.000548	CcSEcCtD
Thalidomide—Mediastinal disorder—Doxorubicin—muscle cancer	4.11e-05	0.000546	CcSEcCtD
Thalidomide—Leukopenia—Methotrexate—muscle cancer	4.1e-05	0.000545	CcSEcCtD
Thalidomide—Chills—Doxorubicin—muscle cancer	4.09e-05	0.000544	CcSEcCtD
Thalidomide—Arrhythmia—Doxorubicin—muscle cancer	4.07e-05	0.000542	CcSEcCtD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—muscle cancer	4.05e-05	0.00107	CbGpPWpGaD
Thalidomide—Alopecia—Doxorubicin—muscle cancer	4.03e-05	0.000536	CcSEcCtD
Thalidomide—NFKB1—Immune System—CD34—muscle cancer	4.03e-05	0.00106	CbGpPWpGaD
Thalidomide—NFKB1—Cellular responses to stress—CDKN2A—muscle cancer	4.01e-05	0.00106	CbGpPWpGaD
Thalidomide—Cough—Methotrexate—muscle cancer	4e-05	0.000532	CcSEcCtD
Thalidomide—Mental disorder—Doxorubicin—muscle cancer	3.99e-05	0.000531	CcSEcCtD
Thalidomide—Convulsion—Methotrexate—muscle cancer	3.97e-05	0.000528	CcSEcCtD
Thalidomide—Vomiting—Etoposide—muscle cancer	3.97e-05	0.000528	CcSEcCtD
Thalidomide—Malnutrition—Doxorubicin—muscle cancer	3.97e-05	0.000528	CcSEcCtD
Thalidomide—Rash—Etoposide—muscle cancer	3.94e-05	0.000524	CcSEcCtD
Thalidomide—Dermatitis—Etoposide—muscle cancer	3.93e-05	0.000523	CcSEcCtD
Thalidomide—NFKB1—Developmental Biology—FOXO1—muscle cancer	3.93e-05	0.00104	CbGpPWpGaD
Thalidomide—Headache—Etoposide—muscle cancer	3.91e-05	0.00052	CcSEcCtD
Thalidomide—Flatulence—Doxorubicin—muscle cancer	3.91e-05	0.00052	CcSEcCtD
Thalidomide—Chest pain—Methotrexate—muscle cancer	3.9e-05	0.000519	CcSEcCtD
Thalidomide—Myalgia—Methotrexate—muscle cancer	3.9e-05	0.000519	CcSEcCtD
Thalidomide—Arthralgia—Methotrexate—muscle cancer	3.9e-05	0.000519	CcSEcCtD
Thalidomide—Tension—Doxorubicin—muscle cancer	3.9e-05	0.000518	CcSEcCtD
Thalidomide—NFKB1—Cellular responses to stress—MDM2—muscle cancer	3.89e-05	0.00103	CbGpPWpGaD
Thalidomide—Dysgeusia—Doxorubicin—muscle cancer	3.89e-05	0.000517	CcSEcCtD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	3.88e-05	0.000515	CcSEcCtD
Thalidomide—Discomfort—Methotrexate—muscle cancer	3.86e-05	0.000513	CcSEcCtD
Thalidomide—Nervousness—Doxorubicin—muscle cancer	3.86e-05	0.000513	CcSEcCtD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	3.84e-05	0.00102	CbGpPWpGaD
Thalidomide—Back pain—Doxorubicin—muscle cancer	3.84e-05	0.00051	CcSEcCtD
Thalidomide—NFKB1—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	3.83e-05	0.00101	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CD34—muscle cancer	3.82e-05	0.00101	CbGpPWpGaD
Thalidomide—Muscle spasms—Doxorubicin—muscle cancer	3.82e-05	0.000507	CcSEcCtD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—MED12—muscle cancer	3.8e-05	0.001	CbGpPWpGaD
Thalidomide—CYP1A2—Arachidonic acid metabolism—PTGS2—muscle cancer	3.79e-05	0.001	CbGpPWpGaD
Thalidomide—Confusional state—Methotrexate—muscle cancer	3.77e-05	0.000501	CcSEcCtD
Thalidomide—Vision blurred—Doxorubicin—muscle cancer	3.74e-05	0.000497	CcSEcCtD
Thalidomide—Infection—Methotrexate—muscle cancer	3.72e-05	0.000494	CcSEcCtD
Thalidomide—Nausea—Etoposide—muscle cancer	3.71e-05	0.000493	CcSEcCtD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—PTGS2—muscle cancer	3.71e-05	0.000979	CbGpPWpGaD
Thalidomide—Ill-defined disorder—Doxorubicin—muscle cancer	3.68e-05	0.00049	CcSEcCtD
Thalidomide—Nervous system disorder—Methotrexate—muscle cancer	3.67e-05	0.000488	CcSEcCtD
Thalidomide—Anaemia—Doxorubicin—muscle cancer	3.67e-05	0.000488	CcSEcCtD
Thalidomide—Thrombocytopenia—Methotrexate—muscle cancer	3.66e-05	0.000487	CcSEcCtD
Thalidomide—NFKB1—Signaling by NGF—MDM2—muscle cancer	3.65e-05	0.000965	CbGpPWpGaD
Thalidomide—Agitation—Doxorubicin—muscle cancer	3.65e-05	0.000485	CcSEcCtD
Thalidomide—Skin disorder—Methotrexate—muscle cancer	3.63e-05	0.000483	CcSEcCtD
Thalidomide—Hyperhidrosis—Methotrexate—muscle cancer	3.62e-05	0.000481	CcSEcCtD
Thalidomide—Malaise—Doxorubicin—muscle cancer	3.58e-05	0.000476	CcSEcCtD
Thalidomide—Vertigo—Doxorubicin—muscle cancer	3.57e-05	0.000474	CcSEcCtD
Thalidomide—Anorexia—Methotrexate—muscle cancer	3.57e-05	0.000474	CcSEcCtD
Thalidomide—Syncope—Doxorubicin—muscle cancer	3.56e-05	0.000473	CcSEcCtD
Thalidomide—Leukopenia—Doxorubicin—muscle cancer	3.55e-05	0.000472	CcSEcCtD
Thalidomide—Palpitations—Doxorubicin—muscle cancer	3.51e-05	0.000466	CcSEcCtD
Thalidomide—Hypotension—Methotrexate—muscle cancer	3.5e-05	0.000465	CcSEcCtD
Thalidomide—NFKB1—Integrated Breast Cancer Pathway—TP53—muscle cancer	3.49e-05	0.000923	CbGpPWpGaD
Thalidomide—Loss of consciousness—Doxorubicin—muscle cancer	3.49e-05	0.000464	CcSEcCtD
Thalidomide—NFKB1—Innate Immune System—FOXO1—muscle cancer	3.47e-05	0.000917	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by NGF—MDM2—muscle cancer	3.47e-05	0.000916	CbGpPWpGaD
Thalidomide—Cough—Doxorubicin—muscle cancer	3.46e-05	0.00046	CcSEcCtD
Thalidomide—Convulsion—Doxorubicin—muscle cancer	3.44e-05	0.000457	CcSEcCtD
Thalidomide—TNF—SIDS Susceptibility Pathways—VEGFA—muscle cancer	3.43e-05	0.000907	CbGpPWpGaD
Thalidomide—Hypertension—Doxorubicin—muscle cancer	3.43e-05	0.000456	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Methotrexate—muscle cancer	3.41e-05	0.000453	CcSEcCtD
Thalidomide—Insomnia—Methotrexate—muscle cancer	3.38e-05	0.00045	CcSEcCtD
Thalidomide—Arthralgia—Doxorubicin—muscle cancer	3.38e-05	0.000449	CcSEcCtD
Thalidomide—Chest pain—Doxorubicin—muscle cancer	3.38e-05	0.000449	CcSEcCtD
Thalidomide—Myalgia—Doxorubicin—muscle cancer	3.38e-05	0.000449	CcSEcCtD
Thalidomide—Anxiety—Doxorubicin—muscle cancer	3.37e-05	0.000448	CcSEcCtD
Thalidomide—Paraesthesia—Methotrexate—muscle cancer	3.36e-05	0.000447	CcSEcCtD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	3.36e-05	0.000446	CcSEcCtD
Thalidomide—Discomfort—Doxorubicin—muscle cancer	3.34e-05	0.000444	CcSEcCtD
Thalidomide—Dyspnoea—Methotrexate—muscle cancer	3.34e-05	0.000443	CcSEcCtD
Thalidomide—NFKB1—Adaptive Immune System—FOXO1—muscle cancer	3.33e-05	0.000881	CbGpPWpGaD
Thalidomide—Somnolence—Methotrexate—muscle cancer	3.33e-05	0.000442	CcSEcCtD
Thalidomide—Dry mouth—Doxorubicin—muscle cancer	3.31e-05	0.000439	CcSEcCtD
Thalidomide—FGFR2—Innate Immune System—FOXO1—muscle cancer	3.29e-05	0.00087	CbGpPWpGaD
Thalidomide—Dyspepsia—Methotrexate—muscle cancer	3.29e-05	0.000438	CcSEcCtD
Thalidomide—Confusional state—Doxorubicin—muscle cancer	3.27e-05	0.000434	CcSEcCtD
Thalidomide—Decreased appetite—Methotrexate—muscle cancer	3.25e-05	0.000432	CcSEcCtD
Thalidomide—TNF—Spinal Cord Injury—TP53—muscle cancer	3.24e-05	0.000857	CbGpPWpGaD
Thalidomide—Oedema—Doxorubicin—muscle cancer	3.24e-05	0.000431	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Methotrexate—muscle cancer	3.23e-05	0.000429	CcSEcCtD
Thalidomide—Fatigue—Methotrexate—muscle cancer	3.23e-05	0.000429	CcSEcCtD
Thalidomide—Infection—Doxorubicin—muscle cancer	3.22e-05	0.000428	CcSEcCtD
Thalidomide—NFKB1—MAPK Signaling Pathway—TP53—muscle cancer	3.21e-05	0.000848	CbGpPWpGaD
Thalidomide—Pain—Methotrexate—muscle cancer	3.2e-05	0.000425	CcSEcCtD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—muscle cancer	3.19e-05	0.000843	CbGpPWpGaD
Thalidomide—Shock—Doxorubicin—muscle cancer	3.19e-05	0.000424	CcSEcCtD
Thalidomide—Nervous system disorder—Doxorubicin—muscle cancer	3.18e-05	0.000422	CcSEcCtD
Thalidomide—Thrombocytopenia—Doxorubicin—muscle cancer	3.17e-05	0.000422	CcSEcCtD
Thalidomide—FGFR2—Adaptive Immune System—FOXO1—muscle cancer	3.16e-05	0.000836	CbGpPWpGaD
Thalidomide—Tachycardia—Doxorubicin—muscle cancer	3.16e-05	0.00042	CcSEcCtD
Thalidomide—Skin disorder—Doxorubicin—muscle cancer	3.15e-05	0.000418	CcSEcCtD
Thalidomide—Hyperhidrosis—Doxorubicin—muscle cancer	3.13e-05	0.000416	CcSEcCtD
Thalidomide—Anorexia—Doxorubicin—muscle cancer	3.09e-05	0.000411	CcSEcCtD
Thalidomide—Feeling abnormal—Methotrexate—muscle cancer	3.08e-05	0.00041	CcSEcCtD
Thalidomide—Gastrointestinal pain—Methotrexate—muscle cancer	3.06e-05	0.000407	CcSEcCtD
Thalidomide—Hypotension—Doxorubicin—muscle cancer	3.03e-05	0.000402	CcSEcCtD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—MED12—muscle cancer	3.01e-05	0.000796	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—FOXO1—muscle cancer	2.99e-05	0.000791	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—FH—muscle cancer	2.99e-05	0.000791	CbGpPWpGaD
Thalidomide—Urticaria—Methotrexate—muscle cancer	2.97e-05	0.000395	CcSEcCtD
Thalidomide—Body temperature increased—Methotrexate—muscle cancer	2.96e-05	0.000393	CcSEcCtD
Thalidomide—Abdominal pain—Methotrexate—muscle cancer	2.96e-05	0.000393	CcSEcCtD
Thalidomide—NFKB1—Cellular responses to stress—VEGFA—muscle cancer	2.96e-05	0.000781	CbGpPWpGaD
Thalidomide—NFKB1—Cellular Senescence—TP53—muscle cancer	2.96e-05	0.000781	CbGpPWpGaD
Thalidomide—Musculoskeletal discomfort—Doxorubicin—muscle cancer	2.95e-05	0.000392	CcSEcCtD
Thalidomide—FGFR2—Disease—ENO2—muscle cancer	2.94e-05	0.000777	CbGpPWpGaD
Thalidomide—Insomnia—Doxorubicin—muscle cancer	2.93e-05	0.00039	CcSEcCtD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	2.92e-05	0.000771	CbGpPWpGaD
Thalidomide—Paraesthesia—Doxorubicin—muscle cancer	2.91e-05	0.000387	CcSEcCtD
Thalidomide—NFKB1—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	2.89e-05	0.000765	CbGpPWpGaD
Thalidomide—Dyspnoea—Doxorubicin—muscle cancer	2.89e-05	0.000384	CcSEcCtD
Thalidomide—Somnolence—Doxorubicin—muscle cancer	2.88e-05	0.000383	CcSEcCtD
Thalidomide—Dyspepsia—Doxorubicin—muscle cancer	2.85e-05	0.000379	CcSEcCtD
Thalidomide—Decreased appetite—Doxorubicin—muscle cancer	2.82e-05	0.000374	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Doxorubicin—muscle cancer	2.8e-05	0.000372	CcSEcCtD
Thalidomide—Fatigue—Doxorubicin—muscle cancer	2.79e-05	0.000371	CcSEcCtD
Thalidomide—Constipation—Doxorubicin—muscle cancer	2.77e-05	0.000368	CcSEcCtD
Thalidomide—Pain—Doxorubicin—muscle cancer	2.77e-05	0.000368	CcSEcCtD
Thalidomide—Hypersensitivity—Methotrexate—muscle cancer	2.76e-05	0.000366	CcSEcCtD
Thalidomide—NFKB1—Immune System—FOXO4—muscle cancer	2.74e-05	0.000723	CbGpPWpGaD
Thalidomide—Asthenia—Methotrexate—muscle cancer	2.68e-05	0.000357	CcSEcCtD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—MED12—muscle cancer	2.67e-05	0.000707	CbGpPWpGaD
Thalidomide—FGFR2—Disease—HMGA1—muscle cancer	2.67e-05	0.000707	CbGpPWpGaD
Thalidomide—Feeling abnormal—Doxorubicin—muscle cancer	2.67e-05	0.000355	CcSEcCtD
Thalidomide—Gastrointestinal pain—Doxorubicin—muscle cancer	2.65e-05	0.000352	CcSEcCtD
Thalidomide—Pruritus—Methotrexate—muscle cancer	2.65e-05	0.000352	CcSEcCtD
Thalidomide—NFKB1—Innate Immune System—KIT—muscle cancer	2.65e-05	0.000699	CbGpPWpGaD
Thalidomide—TNF—Apoptosis—TP53—muscle cancer	2.61e-05	0.000689	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—FOXO4—muscle cancer	2.6e-05	0.000686	CbGpPWpGaD
Thalidomide—Urticaria—Doxorubicin—muscle cancer	2.57e-05	0.000342	CcSEcCtD
Thalidomide—Abdominal pain—Doxorubicin—muscle cancer	2.56e-05	0.00034	CcSEcCtD
Thalidomide—Body temperature increased—Doxorubicin—muscle cancer	2.56e-05	0.00034	CcSEcCtD
Thalidomide—Diarrhoea—Methotrexate—muscle cancer	2.56e-05	0.00034	CcSEcCtD
Thalidomide—NFKB1—Adaptive Immune System—KIT—muscle cancer	2.54e-05	0.000671	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—KIT—muscle cancer	2.51e-05	0.000663	CbGpPWpGaD
Thalidomide—Dizziness—Methotrexate—muscle cancer	2.47e-05	0.000329	CcSEcCtD
Thalidomide—TNF—MAPK Signaling Pathway—TP53—muscle cancer	2.44e-05	0.000646	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—KIT—muscle cancer	2.41e-05	0.000637	CbGpPWpGaD
Thalidomide—FGFR2—Disease—FOXO4—muscle cancer	2.4e-05	0.000634	CbGpPWpGaD
Thalidomide—Hypersensitivity—Doxorubicin—muscle cancer	2.39e-05	0.000317	CcSEcCtD
Thalidomide—Vomiting—Methotrexate—muscle cancer	2.38e-05	0.000316	CcSEcCtD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	2.38e-05	0.000628	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—FH—muscle cancer	2.38e-05	0.000628	CbGpPWpGaD
Thalidomide—Rash—Methotrexate—muscle cancer	2.36e-05	0.000314	CcSEcCtD
Thalidomide—Dermatitis—Methotrexate—muscle cancer	2.36e-05	0.000313	CcSEcCtD
Thalidomide—Headache—Methotrexate—muscle cancer	2.34e-05	0.000312	CcSEcCtD
Thalidomide—Asthenia—Doxorubicin—muscle cancer	2.32e-05	0.000309	CcSEcCtD
Thalidomide—Pruritus—Doxorubicin—muscle cancer	2.29e-05	0.000305	CcSEcCtD
Thalidomide—CYP2E1—Metabolism—FH—muscle cancer	2.24e-05	0.000591	CbGpPWpGaD
Thalidomide—NFKB1—Cellular responses to stress—TP53—muscle cancer	2.23e-05	0.00059	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—FH—muscle cancer	2.23e-05	0.00059	CbGpPWpGaD
Thalidomide—Nausea—Methotrexate—muscle cancer	2.22e-05	0.000295	CcSEcCtD
Thalidomide—Diarrhoea—Doxorubicin—muscle cancer	2.22e-05	0.000295	CcSEcCtD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	2.21e-05	0.000583	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—MED12—muscle cancer	2.19e-05	0.000578	CbGpPWpGaD
Thalidomide—Dizziness—Doxorubicin—muscle cancer	2.14e-05	0.000285	CcSEcCtD
Thalidomide—CYP1A1—Metabolism—FH—muscle cancer	2.11e-05	0.000557	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—MDM2—muscle cancer	2.08e-05	0.00055	CbGpPWpGaD
Thalidomide—Vomiting—Doxorubicin—muscle cancer	2.06e-05	0.000274	CcSEcCtD
Thalidomide—NFKB1—Signaling Pathways—PTCH1—muscle cancer	2.06e-05	0.000544	CbGpPWpGaD
Thalidomide—Rash—Doxorubicin—muscle cancer	2.04e-05	0.000272	CcSEcCtD
Thalidomide—Dermatitis—Doxorubicin—muscle cancer	2.04e-05	0.000271	CcSEcCtD
Thalidomide—Headache—Doxorubicin—muscle cancer	2.03e-05	0.00027	CcSEcCtD
Thalidomide—NFKB1—Immune System—FOXO1—muscle cancer	2.02e-05	0.000534	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—TP53—muscle cancer	2e-05	0.00053	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—MDM2—muscle cancer	2e-05	0.000529	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—MED12—muscle cancer	2e-05	0.000527	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—MDM2—muscle cancer	1.98e-05	0.000522	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—PTCH1—muscle cancer	1.95e-05	0.000516	CbGpPWpGaD
Thalidomide—Nausea—Doxorubicin—muscle cancer	1.92e-05	0.000256	CcSEcCtD
Thalidomide—FGFR2—Immune System—FOXO1—muscle cancer	1.92e-05	0.000507	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—MDM2—muscle cancer	1.9e-05	0.000502	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	1.81e-05	0.000477	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—VEGFA—muscle cancer	1.79e-05	0.000473	CbGpPWpGaD
Thalidomide—FGFR2—Disease—FOXO1—muscle cancer	1.77e-05	0.000468	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—FOXO4—muscle cancer	1.77e-05	0.000468	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CNR1—muscle cancer	1.74e-05	0.000459	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—FH—muscle cancer	1.72e-05	0.000456	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—MED12—muscle cancer	1.71e-05	0.000451	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—MED12—muscle cancer	1.69e-05	0.000447	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—FOXO4—muscle cancer	1.68e-05	0.000444	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CNR1—muscle cancer	1.65e-05	0.000436	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—FH—muscle cancer	1.57e-05	0.000416	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—ENO2—muscle cancer	1.54e-05	0.000407	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—KIT—muscle cancer	1.54e-05	0.000407	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—KIT—muscle cancer	1.46e-05	0.000386	CbGpPWpGaD
Thalidomide—PTGS2—Disease—ENO2—muscle cancer	1.46e-05	0.000386	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—IGF2—muscle cancer	1.42e-05	0.000375	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—VEGFA—muscle cancer	1.36e-05	0.000361	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	1.36e-05	0.00036	CbGpPWpGaD
Thalidomide—FGFR2—Disease—KIT—muscle cancer	1.35e-05	0.000357	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—IGF2—muscle cancer	1.35e-05	0.000356	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—FH—muscle cancer	1.34e-05	0.000355	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—MED12—muscle cancer	1.34e-05	0.000355	CbGpPWpGaD
Thalidomide—PTGS2—Disease—HMGA1—muscle cancer	1.33e-05	0.000351	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—FOXO1—muscle cancer	1.31e-05	0.000345	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—MED12—muscle cancer	1.26e-05	0.000334	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—MED12—muscle cancer	1.26e-05	0.000333	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—FOXO1—muscle cancer	1.24e-05	0.000328	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—ENO2—muscle cancer	1.22e-05	0.000323	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—MDM2—muscle cancer	1.21e-05	0.000321	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	1.21e-05	0.000319	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—MED12—muscle cancer	1.19e-05	0.000315	CbGpPWpGaD
Thalidomide—PTGS2—Disease—FOXO4—muscle cancer	1.19e-05	0.000315	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—ENO2—muscle cancer	1.15e-05	0.000304	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—MDM2—muscle cancer	1.15e-05	0.000304	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—ENO2—muscle cancer	1.15e-05	0.000304	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—ENO2—muscle cancer	1.09e-05	0.000287	CbGpPWpGaD
Thalidomide—FGFR2—Disease—MDM2—muscle cancer	1.06e-05	0.000281	CbGpPWpGaD
Thalidomide—FGFR2—Disease—PTGS2—muscle cancer	1.02e-05	0.000271	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—KIT—muscle cancer	9.96e-06	0.000263	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—MED12—muscle cancer	9.75e-06	0.000258	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—KIT—muscle cancer	9.45e-06	0.00025	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—MED12—muscle cancer	8.89e-06	0.000235	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—ENO2—muscle cancer	8.89e-06	0.000235	CbGpPWpGaD
Thalidomide—PTGS2—Disease—FOXO1—muscle cancer	8.8e-06	0.000232	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	8.49e-06	0.000224	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—ENO2—muscle cancer	8.1e-06	0.000214	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—MDM2—muscle cancer	7.84e-06	0.000207	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—MED12—muscle cancer	7.59e-06	0.000201	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—MDM2—muscle cancer	7.44e-06	0.000197	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	6.95e-06	0.000184	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ENO2—muscle cancer	6.92e-06	0.000183	CbGpPWpGaD
Thalidomide—PTGS2—Disease—KIT—muscle cancer	6.7e-06	0.000177	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	6.34e-06	0.000167	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—VEGFA—muscle cancer	5.96e-06	0.000157	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—VEGFA—muscle cancer	5.65e-06	0.000149	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	5.42e-06	0.000143	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PTGS2—muscle cancer	5.37e-06	0.000142	CbGpPWpGaD
Thalidomide—PTGS2—Disease—MDM2—muscle cancer	5.28e-06	0.000139	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—TP53—muscle cancer	4.5e-06	0.000119	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—TP53—muscle cancer	4.27e-06	0.000113	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PTGS2—muscle cancer	4.01e-06	0.000106	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PTGS2—muscle cancer	4e-06	0.000106	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PTGS2—muscle cancer	3.78e-06	9.99e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PTGS2—muscle cancer	3.1e-06	8.18e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PTGS2—muscle cancer	2.82e-06	7.46e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PTGS2—muscle cancer	2.41e-06	6.37e-05	CbGpPWpGaD
